Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$5.78 USD

5.78
34,571

-0.05 (-0.86%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $5.88 +0.10 (1.73%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J (JNJ) Beats on Q3 Earnings, Cuts 2022 Sales View on Fx Woes

by Zacks Equity Research

J&J (JNJ) beats estimates for third-quarter earnings as well as sales. It lowers the full-year sales guidance. Stock up

Vertex Pharmaceuticals' (VRTX) New AAT Corrector Enters Clinic

by Zacks Equity Research

The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers.

    Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors

    by Zacks Equity Research

    The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.

    AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication

    by Zacks Equity Research

    The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.

    Sanofi (SNY) Gets CHMP Nod for Enjaymo in Hemolytic Anemia

    by Zacks Equity Research

    The CHMP recommends authorizing Sanofi's (SNY) Enjaymo as a treatment for hemolytic anemia in patients with cold agglutinin disease (CAD). The CHMP endorses SNY's RSV vaccine for use in infants.

    Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids

    by Zacks Equity Research

    The EMA's CHMP recommends approving Merck's (MRK) pneumococcal 15-valent conjugate vaccine for expanded use in infants and children. The vaccine received similar approval from the FDA in June 2022.

    Pfizer's (PFE) Late-Stage Meningococcal Jab Study Meets Goal

    by Zacks Equity Research

    Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.

    Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal

    by Zacks Equity Research

    Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.

    Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer

    by Zacks Equity Research

    Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.

    FDA Panel to Review Perrigo's (PRGO) OTC Birth Control Pill

    by Zacks Equity Research

    The FDA schedules a joint advisory committee meeting in November 2022 to review Perrigo's (PRGO) regulatory filing for the first-ever over-the-counter birth control pill.

    Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why

    by Zacks Equity Research

    Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end

    Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug

    by Zacks Equity Research

    The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.

    Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA

    by Zacks Equity Research

    The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.

    Kamada (KMDA) Q2 Earnings Beat Estimates

    by Zacks Equity Research

    Kamada (KMDA) delivered earnings and revenue surprises of 450% and 1.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -23.26% and 63.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.76% and 77.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Precigen, Inc. (PGEN) Reports Q2 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 18.75% and 83.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Codexis (CDXS) delivered earnings and revenue surprises of 71.43% and 1.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Sangamo (SGMO) delivered earnings and revenue surprises of 6.25% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Kamada (KMDA) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Kamada (KMDA) delivered earnings and revenue surprises of -166.67% and 8.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?